Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04971200
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:09.006556+00:00
Published At
2024-11-12T00:00:00+00:00
Record Updated At
2024-11-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Skin and Connective Tissue Diseases", "Skin Diseases", "Pigmentation Disorder", "Hypopigmentation", "Biologic", "Vitiligo"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-11-12"
protocolSection.identificationModule.nctId
"NCT04971200"
protocolSection.identificationModule.officialTitle
"Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Skin and Connective Tissue Diseases (protocolSection.conditionsModule.conditions)
  • Skin Diseases (protocolSection.conditionsModule.conditions)
  • Pigmentation Disorder (protocolSection.conditionsModule.conditions)
  • Hypopigmentation (protocolSection.conditionsModule.conditions)
  • Biologic (protocolSection.conditionsModule.conditions)
  • Vitiligo (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.